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Background: This study aimed to compare and externally validate risk scores developed to predict incident colorectal cancer
(CRC) that include variables routinely available or easily obtainable via self-completed questionnaire.
Methods: External validation of fourteen risk models from a previous systematic review in 373 112 men and women within the UK
Biobank cohort with 5-year follow-up, no prior history of CRC and data for incidence of CRC through linkage to national cancer
registries.
Results: There were 1719 (0.46%) cases of incident CRC. The performance of the risk models varied substantially. In men, the
QCancer10 model and models by Tao, Driver and Ma all had an area under the receiver operating characteristic curve (AUC)
between 0.67 and 0.70. Discrimination was lower in women: the QCancer10, Wells, Tao, Guesmi and Ma models were the best
performing with AUCs between 0.63 and 0.66. Assessment of calibration was possible for six models in men and women. All would
require country-specific recalibration if estimates of absolute risks were to be given to individuals.
Conclusions: Several risk models based on easily obtainable data have relatively good discrimination in a UK population.
Modelling studies are now required to estimate the potential health benefits and cost-effectiveness of implementing stratified
risk-based CRC screening.
Colorectal cancer (CRC) is the second leading cause of cancer-
related death in Europe and the United States (Stewart and
Kleihues, 2003). Survival is strongly related to stage at diagnosis
(Cancer Research UK, 2009). There is good evidence that screening
adults in the general population who are at average risk using
faecal occult blood testing (FOBt), flexible sigmoidoscopy or
colonoscopy reduces CRC incidence and mortality (Hardcastle
et al, 1996; Kronborg et al, 1996; Lindholm et al, 2008; Holme et al,
2013; Lin et al, 2016). As a result, CRC screening for individuals
above a defined age has been introduced in most countries with a
high CRC incidence (Schreuders et al, 2015). For example,
currently in the US, the US Preventive Services Task Force
recommends all men and women are invited for screening at age
50 years (US Preventive Services Task Force et al, 2016) and in
England all men and women aged 60 to 74 are offered FOBt every
2 years (Public Health England, 2015).
However, as with all screening programmes, CRC screening has
the potential to cause harm, both directly to those screened and
indirectly through diversion of resources away from other services.
Targeted or stratified screening could potentially provide a way of
reducing complication rates and demand on services by better
identifying those who are more likely to benefit from screening and
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early intervention and potentially inviting them earlier or more
frequently.
Such an approach requires risk prediction models capable of
stratifying the population. We have previously published a
systematic review of risk prediction models for CRC and identified
40 models that could potentially be used for this purpose (Usher-
Smith et al, 2015). They range from models including only data
routinely available from electronic health records such as age,
gender and body mass index (BMI), to more complex models
containing detailed information about lifestyle factors and genetic
biomarkers. Including models published since that review, of the
26 that include variables routinely available or easily obtainable via
self-completed questionnaire, where reported (n¼ 12), half the
models have acceptable-to-good discriminatory ability (C-statistic
40.7) in the derivation sample. However, only five have been
validated in external populations (C-statistic 0.60–0.71) and none
in a UK population.
UK Biobank is the largest population-based cohort in the UK
(Allen et al, 2012). In order to inform future risk stratified
screening approaches in the UK, we aimed to assess the
performance of risk scores that have been developed to identify
individuals at higher risk of developing CRC and include only
variables routinely available or easily obtainable via self-completed
questionnaire, in the UK Biobank cohort.
MATERIALS AND METHODS
We performed an external validation of risk models following the
TRIPOD (transparent reporting of a multivariable prediction
model for individual prognosis or diagnosis) guideline (Collins
et al, 2015).
Selection of risk prediction models. We identified 40 risk
prediction models for either CRC, colon cancer or rectal cancer
from our recent systematic review and two that had been published
since the end of the search period for that review (March 2014) and
November 2016. If insufficient data were provided to operationa-
lise the risk scores in the published articles, we contacted authors
asking for the additional data. We excluded 16 that included either
biochemical or genetic biomarkers. In three, it was not possible to
operationalise the risk score, either because details of how the co-
variates were incorporated in the final model were not provided
(Bener et al, 2010), the model developed was a decision tree (Camp
and Slattery, 2002), or the model required data on risk factors over
20 years prior to baseline (Wei EK et al, 2009). A further two
(Almurshed, 2009; Taylor et al, 2011) included risk markers for
which there is no comparable variable available within the UK
Biobank (region in Riyadh, Saudi Arabia and knowledge of a high-
fibre diet, and second and third degree family history, respectively)
(Supplementary Figure 1). As Ma et al (2010), Freedman et al
(2009) and Driver et al (2007) developed separate models for CRC,
colon and rectal cancer on the same data set, we included only the
models for CRC. This meant we included 14 risk models in our
analysis, 13 with CRC as the outcome and 1 with colon cancer as
the outcome (Colditz et al, 2000). Details of these models,
including the study design, method used to develop them and
the risk factors included in each are given in Table 1. Except for the
models by Colditz et al (2000), Johnson et al (2013) and Wei Y-S
et al (2009), age was included in all the models and alcohol, BMI,
smoking and family history were each included in over half. Only
one model included sex (Tao et al, 2014), whereas six were
developed to be applicable to men (Wells et al, 2014; Driver et al,
2007; Freedman et al, 2009; Ma et al, 2010; Hippisley-Cox and
Coupland, 2015) and three to women (Wells et al, 2014; Freedman
et al, 2009; Hippisley-Cox and Coupland, 2015). Details of the full
equations for the risk models are given in Supplementary Table 1.
Validation cohort. UK Biobank is the largest population-based
cohort in the UK with over 500 000 people recruited during 2006–
2011. Details of recruitment and data collection are provided in
detail elsewhere (Allen et al, 2012). In brief, all people aged 40–69
years who were registered with the National Health Service and
lived within B25 miles of one of the 22 study assessment centres
across the UK were invited to participate. From 9.2 million
invitations, 503 325 were recruited (5.5%) and attended an
assessment centre at which baseline data was collected on their
lifestyle, environment, medical history and body composition using
touchscreen questionnaires, interviews and physical measure-
ments. The cohort is representative of the UK general population
with respect to age, sex, ethnicity and deprivation within the age
range recruited, it is however not representative with respect to a
variety of sociodemographic, physical, lifestyle and health-related
characteristics, with evidence of a ‘healthy volunteer’ selection bias
(Fry et al, 2017). Compared with the population of England in
2012 from the Office of National Statistics, incidence rates for CRC
per 100 000 person-years were lower for all ages between 45 and 74
years except for 50–54 years (Fry et al, 2017). For example, at age
60–64, incidence rates in men and women in UK Biobank were
141.2 and 84, respectively, compared with 159.9 and 92.5 in the
general population.
Data on cancer incidence up to 30 September 2014 is available
for each participant through linkage to national cancer registries.
We excluded from the analysis participants with a diagnosis
of CRC (ICD9 153.0–153.9, 154.0, 154.1 and 154.8 and ICD10
C18.0–C18.9, C19, C20 and C21.8) prior to recruitment.
Of the 502 633 participants within the UK Biobank cohort, 2331
had a prior diagnosis of CRC, three had a date of death prior to
baseline recorded and 127 187 did not have follow-up for 5 years.
We therefore included 373 112 participants in our primary
analysis. Among those there were 1719 (0.46%) cases of incident
CRC.
Risk factor and outcome variables. For each risk factor, we used
data collected at the baseline assessment at cohort entry. Full
details of the definition of each risk factor and how we
operationalised them in the UK Biobank data set and handled
missing data are given in Supplementary Table 2. In all cases, we
matched variables from the Biobank data set as closely as possible
to those described in each model and if there was not an exact
match we derived proxy variables. In most cases, we were able to
do this by combining existing variables. For some, this was simple,
for example, summing beef, pork and lamb consumption to derive
a variable for red meat. In some, however, it was more complex
and required a number of assumptions. In other cases, where an
exact variable did not exist in the Biobank cohort, we derived
variables from similar questions. For example, no data are available
in Biobank for historic use of aspirin or non-steroidal anti-
inflammatory drugs (NSAIDs). We therefore used responses to the
question ‘Do you regularly take any of the following? Aspirin,
ibuprofen, paracetamol, codeine’ or the presence of a code
indicating NSAID use in the list of current regular treatments to
categorise individuals as regular or current users and used the
mean duration of use from the literature (Hoffmeister et al, 2007)
to estimate duration of use.
The outcome for each risk model was newly diagnosed CRC
using the data from linked cancer registries (ICD10 C18.0–C18.9,
C19, C20 and C21.8).
Data analysis. For all prediction models, we first computed the
predicted probability for each participant at baseline. We then
assessed the discrimination and calibration of the risk scores.
Although some risk models had been developed in all male
populations, we assessed the performance in both men and
women. Except for the Freedman models (Freedman et al, 2009)
where the Gauss program available to calculate the risk scores
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prevents calculation of risk for those outside the defined age range
(50–89 years), we assessed the performance of all the models over
the full range of UK Biobank participants.
For our primary analysis, we used a ‘complete-case’ approach,
including only those for whom a risk score based on all risk factors
could be computed and who had 5-year follow-up. This was done
on an individual risk score basis so the sample size varies between
scores. To reflect the clinical application of risk scores, we did not
exclude those who did not have 5-year follow-up due to death. We
treated the outcome as a binary variable (developed CRC or did
not develop CRC) and compared the overall discriminative ability
of the models numerically with the area under the receiver
operating characteristic curve (AUC). We also calculated sensitiv-
ity, specificity, positive- and negative-likelihood ratios (LRþ and
LR ) and the positive and negative predictive values (PPV and
NPV) using a cutoff value for each risk score chosen such that 10%
of the population had values above the cutoff; the procedure was
then repeated using cutoffs where 20, 80 and 90% had values above
the cutoff.
If data were available in the original published reports or from
authors, we assessed calibration graphically by comparing the
predicted risk with the observed percentage of those who
developed CRC over the 5-year follow-up period stratified by
deciles and calculated Hosmer–Lemeshow statistics. QCancer10
was the only model to provide data on 5-year risk. All the other
models predicted risk over 10 or 20 years and this required
converting the predicted risks to risks over 5 years. We did this first
assuming a constant risk over time as the rate of incident CRC
observed within the UK Biobank cohort was constant over the
follow-up period. We then repeated the analysis assuming risk
doubles every 5 years, in line with reported increasing incidence
rates with increasing age (Cancer Research UK, 2017). To allow
comparison across all the models, we also used this same approach
for the QCancer10 model.
We then carried out a number of sensitivity analyses. In the first
set, we explored the impact of missing data, comparing the
performance of the models using the complete-case analysis with
an extreme case in which risk factors with45% missing data were
coded as the 90th or 10th percentile values for continuous variables
and present or absent for dichotomous. Second, in view of the
absence of data on historic aspirin or NSAID use and inability to
distinguish between oestrogen-containing contraceptive pills and
progesterone-only pills, we assessed the performance of the models
excluding variables for aspirin, NSAIDs or hormonal medication.
Third, recognising that these models may be used in multiple
countries, we assessed the performance of the QCancer10 model
for men without the term for deprivation. As participants with
previous colorectal polyps or a diagnosis of inflammatory bowel
disease (IBD) would likely be in surveillance programmes, we also
assessed the discrimination after excluding those individuals with a
history of a colorectal polyp or diagnosis of IBD at baseline.
Finally, we compared the performance of the risk scores using an
open cohort design, that is to say including participants with o5
years follow-up. In that analysis, we used Harrell’s C-statistic to
assess discrimination as it accounts for censoring in survival
models (Chambless and Diao, 2006).
All analyses were carried out in Stata 13.1 (StataCorp, 2013).
RESULTS
The characteristics of the study population are shown in Table 2.
Compared to those who did not develop CRC, those who did were
on average older and more likely to be male, report a family history
Table 1. Details of the development and factors included in each of the risk scores included in validation study
Factors included in score
Author, year Country
Cancer
outcome
Study
design
Model
type Age Sex Ethnicity BMI FH Smoking Alcohol
Physical
activity
Red
meat
Aspirin/
NSAIDs Other
Colditz et al, 2000 USA Colon Expert
consensus
Expert
consensus
K K K K K K Vegetables, height, HRT,
birth control pills.
multivitamin use, IBD,
saturated fat, calcium and
vitamin D supplements
Driver et al, 2007 USA Colorectal Cohort Logistic
regression
K A K K K
Freedman et al,
2009
USA Colorectal
(male)
Case–control Logistic
regression
K B K K K K K K Vegetables, previous
sigmoidoscopy or
colonoscopy, previous
polyps
Freedman et al,
2009
USA Colorectal
(female)
Case–control Logistic
regression
K B K K K K K Vegetables, previous
sigmoidoscopy or
colonoscopy, previous
polyps, oestrogen use
Guesmi et al,
2010
Tunisia Colorectal Case–control Logistic
regression
K Processed meat, milk
Johnson et al,
2013
Worldwide Colorectal Meta-analysis Meta-analysis K K K K K K K IBD, hormone therapy,
processed meat
Ma et al, 2010 Japan Colorectal Cohort Cox
regression
K A K K K K
Ma et al, 2010 Japan Colorectal Cohort Simple score K A K K K K
Tao et al, 2014 Germany Colorectal Cross-
sectional
Logistic
regression
K K K K K K K Previous polyp, previous
colonoscopy
Wei Y-S et al,
2009
China Colorectal Case–control Logistic
regression
K K K K
Hippisley-Cox and
Coupland, 2015
(QCancer10)
UK Colorectal
(male)
Cohort Cox
regression
K B K K K K K Deprivation, blood cancer,
ulcerative colitis, lung cancer,
oral cancer, polyps, diabetes
Hippisley-Cox and
Coupland,
2015 (QCancer10)
UK Colorectal
(female)
Cohort Cox
regression
K B K K K K Breast cancer, cervical
cancer, ulcerative colitis,
ovarian cancer, polyps,
diabetes, uterine cancer
Wells et al, 2014 USA Colorectal
(male)
Cohort Cox
regression
K B K K K K K K K K Years of education,
multivitamins, diabetes
Wells et al, 2014 USA Colorectal
(female)
Cohort Cox
regression
K B K K K K K K Years of education,
multivitamins, diabetes,
oestrogen
Abbreviations: A¼model applicable to male only; B¼different models for male and female; BMI¼body mass index; FH¼ family history; IBD¼ inflammatory bowel disease; NSAIDs¼non-
steroidal anti-inflammatory drugs.
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of CRC, be a former smoker, eat red meatX3 times per week, use
NSAIDs or aspirin currently and have a higher BMI. There was
o5% missing data for all the risk factors included in the models
with the exception of physical activity for which data were missing
for 12% of participants.
Discrimination. Figures 1A and B show the AUC for the 10
models in men and women, respectively. The three models by
Colditz et al (2000), Johnson et al (2013) and Wei Y-S et al (2009)
that do not include age have the poorest discrimination with all
having AUCso0.6. In men, the QCancer10 model (Hippisley-Cox
and Coupland, 2015) and models by Tao et al (2014), Driver et al
(2007) and Ma et al (2010) all had AUCs over 0.67. In general, the
discrimination was less good in women. Of the models developed
for women, the QCancer10 (Hippisley-Cox and Coupland, 2015),
Tao et al (2014), Guesmi et al (2010) and Wells et al (2014) models
were the best performing with AUCs between 0.63 and 0.66. When
applied to women, the Driver et al, (2007) and Ma et al (2010)
models had AUCs of 0.63 (95% CI: 0.61–0.65) and 0.64 (95% CI:
0.62–0.66), respectively.
The sensitivity, likelihood ratios and PPV and NPVs are also
shown in Tables 3 and 4. By targeting the 10% with the
highest risk, the QCancer10 (Hippisley-Cox and Coupland,
2015), Ma et al (2010) and Wells et al (2014) models identified
between 24% and 26% of men and 19% and 20% of women who
went on to develop CRC. In women the Johnson model (Johnson
et al, 2013) also had a sensitivity of 19.8 for the top 10%. This
compares to 17 and 16% for the UK screening programme age
threshold for men and women, respectively. Among those with the
highest 20% risk, this increased to 37–43% for men and 33–36%
for women, compared with 31% for the UK screening programme
age threshold. The Driver model (Driver et al, 2007), which
includes only age, BMI, smoking status and whether individuals
consume alcohol, identified 20.2% of men and 17.4% of women
who went on to develop CRC by targeting the 10% at highest risk
and 38.5% of men and 30.9% of women by targeting the 20% at
highest risk. The NPVs were high and comparable (499.4) for all
models.
Calibration. Assessment of calibration was only possible for six of
the models Driver et al, 2007; Freedman et al, 2009; Ma et al, 2010;
simple; Ma et al, 2010 (Cox); QCancer10 (Hippisley-Cox and
Coupland, 2015) and Wells et al, 2014. Figures 2A and B show the
observed and predicted risks of CRC for those models for men and
women. When the risk of CRC over time was assumed to be
constant all overestimated risk, particularly at higher deciles of risk
and in the models developed in men when applied to women
(Hosmer–Lemeshow Po0.0001 for all risk models). The two Ma
models and Freedman model also overestimated risk in both men
and women when the risk was assumed to double every 5 years, while
the Driver model, which was the only model initially developed to
estimate risk over a 20-year period, underestimated risk. The
predicted risks from the QCancer10 and Wells models more closely
matched the observed risks when the risk was assumed to double
every 5 years, although overall calibration remained poor (Hosmer–
Lemeshow Po0.05). When using the published algorithm for 5-year
risk for the QCancer10 models, both the male and female models
also overestimated risk (Hosmer–Lemeshow Po0.05)
(Supplementary Figure 2).
Sensitivity analyses. The results from all the sensitivity analyses
(Supplementary Tables 3 and 4) were consistent with the main
analysis: the confidence intervals for the AUC and the C-statistic in
the open cohort analysis (Supplementary Table 5) for each model
overlapped the AUC obtained in the main closed-cohort analysis.
As the Colditz model (Colditz et al, 2000) was developed to predict
colon cancer rather than CRC, we also assessed the discrimination
with colon cancer as the outcome. The AUCs for that analysis were
also within the confidence interval of those with CRC as the
outcome (men AUC 0.57 (95% CI 0.55–0.59); women AUC 0.51
(95% CI 0.49–0.54)).
Table 2. Characteristics of participants in the UK Biobank
cohort with at least 5 years follow-up used for validation,
including distribution of variables between those with and
without incident colorectal cancer
No incident
CRC,
n¼371393
Incident
CRC,
n¼1719
% with
incident
CRC
Age (years)
Mean (SD) 56.4 (8.1) 61.3 (6.3) —
Missing (%) 0 (0) 0 (0) —
Sex
Male (%) 168 757 (45.4) 965 (56.1) 0.57
Female (%) 202 636 (54.6) 754 (43.9) 0.37
Missing (%) 0 (0) 0 (0) —
Ethnicity
White (%) 354 928 (95.6) 1 668 (97.0) 0.47
Other (%) 14 787 (4.0) 43 (2.5) 0.29
Missing (%) 1678 (0.5) 8 (0.5) 0.47
Years of full-time education
Mean (SD) 13.0 (2.8) 12.7 (2.8) —
Missing (%) 7677 (2.1) 34 (2.0) —
BMI (kg/m2)
o20 (%) 8631 (2.3) 31 (1.8) 0.35
20–24.9 (%) 113 797 (30.6) 449 (26.3) 0.39
25–29.9 (%) 157 093 (42.3) 778 (45.6) 0.50
Z30 (%) 90 008 (24.2) 449 (26.3) 0.50
Missing (%) 1864 (0.5) 12 (0.7) 0.64
Family history of CRCa
Yes (%) 40 131 (10.8) 249 (15.2) 0.62
No (%) 316 589 (85.2) 1392 (84.8) 0.44
Missing (%) 14 673 (4.0) 78 (4.5) 0.53
Smoking status
Never (%) 201 821 (54.3) 760 (44.6) 0.38
Former (%) 127 793 (34.4) 767 (45.0) 0.60
Current (%) 39 864 (10.7) 177 (10.4) 0.44
Missing (%) 1915 (0.5) 15 (0.9) 0.78
Alcohol drinking status
Non (%) 15 730 (4.2) 59 (3.4) 0.37
Former (%) 13 194 (3.6) 66 (3.9) 0.50
Current (%) 341 591 (92.0) 1589 (92.7) 0.47
Missing (%) 878 (0.2) 5 (0.3) 0.57
Physical activity (MET-h/d) —
Mean (SD) 28.3 (5.5) 28.6 (5.8) —
Missing (%) 43 461 (11.7) 235 (13.7)
Red meat consumption
o3 times/week (%) 283 455 (76.3) 1244 (72.4) 0.44
Z3 times/week (%) 82 959 (22.3) 452 (26.3) 0.54
Missing (%) 4979 (1.3) 23 (1.3) 0.46
Current aspirin use
Yes (%) 55 702 (15.0) 347 (20.5) 0.62
No (%) 311 590 (83.9) 1348 (79.5) 0.43
Missing (%) 4101 (1.1) 24 (1.4) 0.58
Current NSAID use
Yes (%) 116 057 (31.3) 568 (33.5)) 0.49
No (%) 251 5775 (67.7) 1129 (66.5) 0.45
Missing (%) 3759 (1.0) 22 (1.3) 0.58
Fruit and vegetable consumption
o5 portions/day (%) 82 361 (22.2) 389 (22.6) 0.47
Z5 portions/day (%) 280 637 (75.6) 1290 (75.0) 0.46
Missing (%) 8395 (2.3) 40 (2.3) 0.48
Abbreviations: BMI¼body mass index; CRC¼ colorectal cancer; MET-h/d¼Metabolic
Equivalent of Task hours per day; NSAID¼ non-steroidal anti-inflammatory drug.
aOne of more of mother, father or sibling.
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DISCUSSION
Principal findings. In this large, UK population-based study, we
found that the performance of published risk models for CRC
varied substantially. Of the 14 risk models for CRC identified from
an update of an existing systematic review (Usher-Smith et al,
2015), the QCancer10 model (Hippisley-Cox and Coupland, 2015)
and models by Tao et al (2014), Driver et al (2007) and Ma et al
(2010) had the highest discrimination in men with all having
AUCs over 0.67. Discrimination was lower for women: the
QCancer10 (Hippisley-Cox and Coupland, 2015), Ma et al
(2010) and Wells et al (2014) models were the best performing
with AUCs between 0.64 and 0.66. The risk models that do not
include age Colditz et al (2000); Johnson et al (2013) and Wei Y-S
et al (2009) performed least well. The QCancer10 model
(Hippisley-Cox and Coupland, 2015), Tao et al (2014) and Ma
et al (2010) had the highest sensitivities in men. For each of these
models, the top 10% included between 24% and 26% of those who
went on to develop CRC, and the top 20% between 41% and 43%.
For women, the models by Wells et al (2014), Ma et al (2010), and
QCancer10 (Hippisley-Cox and Coupland, 2015) also had the
highest sensitivities, alongside the model by Johnson et al (2013).
Calibration was sensitive to assumptions about the change in risk
over time, with all models overestimating risk when risk was
assumed to be constant over time and estimated risks more closely
matching observed risk when risk for each individual was assumed
to double every 5 years.
The finding that the three poorest performing risk models in
both men and women Colditz et al (2000),Johnson et al (2013);
Wei Y-S et al (2009) are the ones that do not include age, and of
those only the Colditz model in men performs better than chance,
highlights the importance of older age as a risk factor for
development of cancer. We also found that discrimination is
poorer in women than in men for all except the Wells model
(Wells et al, 2014). This may relate to a difference in the reporting
of risk factors or a difference in the aetiology of the disease between
sexes. For example, it is known that a higher proportion of women
present with right-sided colon cancer than men (Hansen and Jess,
2012). The molecular and pathological characteristics of CRC differ
depending on tumour location and studies have reported different
associations between dietary factors (Kim et al, 2015) and CRC risk
by sex. The impact of female hormonal factors may also be
complex, with previous and current hormone replacement therapy
associated with a decreased risk, while chronic endogenous
oestrogen exposure may be associated with an increased risk in
postmenopausal women (Lin et al, 2012; Bae et al, 2013).
The finding that the only risk model included which was
developed in a UK population, QCancer10, had the highest
discrimination in this UK cohort also suggests that the distribution
and impact of risk factors may differ geographically. Country-
specific risk models may therefore be preferable when implement-
ing stratified screening programmes.
Strengths and limitations. To our knowledge, this is the first
study to directly compare multiple published risk prediction
models for CRC in the same population, and the first to externally
validate any risk prediction models in a UK population. By
identifying models for inclusion from an update of an existing
systematic review (Usher-Smith et al, 2015) and contacting authors
concerning missing data, we have been able to include 14 risk
models developed around the world. There were, however, six
identified models that we were unable to validate: four where it was
not possible to operationalise the risk score and two where
variables were not present in the UK Biobank cohort. We think it is
unlikely that the models by Almurshed, Taylor or Benner
(Almurshed, 2009; Bener et al, 2010; Taylor et al, 2011) would
perform better than those included as they do not include age and
neither of the models by Camp and Slattery (2002) or Wei EK et al,
(2009) have been externally validated, but both had only moderate
discrimination in development populations (AUC 0.61). Advan-
tages of using the UK Biobank cohort include the large size,
comprehensive phenotyping, completeness of data and linkage to
national cancer registries. However, the response rate to invitations
to take part was only 5.5% (Allen et al, 2012). While the cohort is
representative of the UK general population with respect to age,
sex, ethnicity and deprivation within the age range recruited, it is
however not representative with respect to a variety of socio-
demographic, physical, lifestyle and health-related characteristics
(Fry et al, 2017). For example, mean BMI in the UK Biobank men
and women aged 55–64 years was 27.9 and 27.3, respectively,
compared with 28.5 and 28.0 in the general population who took
part in the Health Survey for England 2008, UK Biobank men and
women were less likely to be current smokers than the general
population and incidence rates of CRC were lower in the UK
Biobank population. Although representative population samples
may not always be necessary to make generalisable conclusions
about associations between exposures and disease (Collins, 2012),
the performance of risk prediction models should ideally be
assessed within the population in which they are going to be used
(Collins et al, 2015). The performance of the risk models in this
study may, therefore, not reflect those in the entire UK population
or other populations and the ‘healthy volunteer’ selection bias may
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Figure 1. Model discrimination. Area under the receiver operating
characteristic curve for the risk models in (A) men and (B) women.
*Models originally only developed in men.
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partly explain the finding that some of the models overestimated
absolute risk. This ‘healthy volunteer’ bias will have less influence
over the relative risk, and hence discrimination of the models.
Nevertheless, the average population risk may be lower in the UK
Biobank than across the whole UK population and the discrimina-
tion likely underestimated due to a narrower range of risk. The
relatively short duration of follow-up to date within UK Biobank
also means that we were only able to evaluate calibration with
estimates of risk over a 5-year period. To do this required us to
make assumptions about the pattern of CRC risk over time.
While this increases the uncertainty for each model, by choosing to
present data for the situation in which risk is constant over time, as
in our data, and one in which it doubles every 5 years, we provide
the range of likely values. We were also only able to do
this for models in which it was possible to calculate an estimated
absolute risk from the original publication. It is also not possible
from the data to distinguish between those individuals diagnosed
with incident CRC through surveillance and those diagnosed
following symptoms. Although the quality of the evidence is low, a
recent Cochrane review showed that colonoscopic surveillance in
patients with IBD may reduce the development of CRC
and the rate of CRC-associated death through early detection
(Bye et al, 2017). The incidence of CRC over the 5-year period used
in this study may therefore be either higher or lower. Our
sensitivity analysis excluding individuals likely to be in a
surveillance programme (those with a previous polyp or diagnosis
of IBD), however, showed no difference in the discrimination of
the models.
We also excluded two models identified from our systematic
review because they included variables not present in UK Biobank,
and had to derive proxy variables if there were no exact matches
for many of the risk models. In most cases, we were able to do this
by simply combining existing variables, but some, notably aspirin/
NSAID use and oestrogen use, required a number of assumptions
that may have reduced AUC values. For example, the absence of
data in UK Biobank on long-term use of aspirin/NSAIDs meant
that we relied on responses to questions about use of aspirin or
ibuprofen and the current medication lists to identify current users
and were unable to identify past users. In doing this, we may have
overestimated those regularly taking aspirin/NSAIDs and are
unable to distinguish between those taking aspirin/NSAIDs at high
doses for short-term pain relief or low doses for long-term
prevention of cardiovascular diseases. This may explain the finding
that a greater proportion of those who developed CRC were coded
within our data as current users compared to those who did not
develop CRC, which is counter to evidence from aetiological and
mechanistic studies (Rigas and Tsioulias, 2015; Burn and Sheth,
2016). We think it is unlikely that this is due to reverse causality as
it is not current practice to recommend aspirin or NSAIDs to those
at high risk of CRC. Instead, as the population who develop CRC
are older and conditions requiring medication for pain relief are
more common with age, this may be explained by confounding. As
a consequence of this, the contribution of aspirin/NSAID use in the
five models (Colditz et al, 2000; Freedman et al, 2009; Tao et al,
2014; Wells et al, 2014; Johnson et al 2013) that include that
variable will be reduced and the discrimination potentially
underestimated. This is further supported by our sensitivity
analysis in which removing the terms for aspirin/NSAID use did
not affect the AUC. The models that did not include any variables
for which assumptions had been made were those by Driver, Ma,
Table 3. Discriminatory performance measures for each of the risk models for 5-year risk of developing colorectal cancer in men
Colditz Driver Freedman Guesmi Johnson
Ma
(simple)
Ma (Cox) QCancer10 Tao Wei Y-S Wells
Total n
n¼
139257
n¼
167762
n¼
101530
n¼
168825
n¼
169722
n¼
150386
n¼
150386
n¼
158024
n¼
149693
n¼
160256
n¼
140749
Incident
CRC
n¼761 n¼946 n¼685 n¼961 n¼965 n¼830 n¼830 n¼884 n¼825 n¼898 n¼764
Top 10%
Sensitivity 13.8 20.2 21.5 11.1 12.2 22.5 24.7 24.9 26.4 14.5 22.6
Specificity 90.0 90.1 90.1 90.0 90.0 90.1 90.1 90.1 90.1 90.0 90.1
LRþ 1.38 2.03 2.16 1.11 1.22 2.27 2.49 2.51 2.67 1.45 2.28
LR 0.96 0.89 0.87 0.99 0.98 0.86 0.84 0.83 0.82 0.95 0.86
PPV (%) 0.8 1.1 1.4 0.6 0.7 1.2 1.4 1.4 1.5 0.8 1.2
NPV (%) 99.5 99.5 99.4 99.4 99.4 99.5 99.5 99.5 99.5 99.5 99.5
Top 20%
Sensitivity 25.8 38.5 35.3 29.9 23.2 40.0 42.8 42.8 41.3 23.3 36.5
Specificity 80.0 80.1 80.1 80.1 80.0 80.1 80.1 80.1 80.1 80.0 80.1
LRþ 1.29 1.93 1.78 1.50 1.16 2.01 2.15 2.15 2.08 1.16 1.83
LR 0.93 0.77 0.81 0.88 0.96 0.75 0.71 0.71 0.73 0.96 0.79
PPV (%) 0.7 1.1 1.2 0.8 0.7 1.1 1.2 1.2 1.1 0.7 1.0
NPV (%) 99.5 99.6 99.5 99.5 99.5 99.6 99.6 99.6 99.6 99.5 99.6
Top 80%
Sensitivity 86.2 95.2 90.7 96.1 71.4 97.0 96.7 97.1 95.6 84.2 85.9
Specificity 20.0 20.1 20.1 20.1 20.0 20.1 20.1 20.1 20.1 20.0 20.0
LRþ 1.08 1.19 1.13 1.20 0.89 1.21 1.21 1.21 1.20 1.05 1.07
LR 0.69 0.24 0.47 0.19 1.43 0.16 0.16 0.15 0.22 0.79 0.71
PPV (%) 0.6 0.7 0.8 0.7 0.5 0.7 0.7 0.7 0.7 0.6 0.6
NPV (%) 99.6 99.9 99.7 99.9 99.2 99.9 99.9 99.9 99.9 99.6 99.6
Top 90%
Sensitivity 94.3 98.0 96.6 99.1 82.7 98.8 99.0 99.1 97.5 91.4 88.7
Specificity 10.0 10.0 10.0 10.1 10.0 10.0 10.1 10.1 10.0 10.0 10.0
LRþ 1.05 1.09 1.07 1.10 0.92 1.10 1.10 1.10 1.08 1.02 0.99
LR 0.56 0.20 0.33 0.09 1.74 0.12 0.10 0.09 0.25 0.86 1.13
PPV (%) 0.6 0.6 0.7 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.5
NPV (%) 99.7 99.9 99.8 99.9 99.0 99.9 99.9 99.9 99.8 99.5 99.4
Abbreviations: LRþ ¼positive likelihood ratio; LR ¼ negative likelihood ratio; NPV¼negative predictive value; PPV¼positive predictive value.
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Wei Y-S and the QCancer10 models. This may in part explain why
the Driver, Ma and QCancer10 models performed better than
many others in this analysis, particularly in men. The limitations of
using the AUC to compare across the risk models must also be
appreciated. While the AUC is widely considered the standard
measure of discrimination and summarises the model performance
over all possible thresholds, it does not distinguish between false-
positive and false-negative misclassification and is independent of
prevalence (Lobo et al, 2007). Other approaches, including net
reclassification, have been developed to account for these limitations
but they are more relevant for detailed comparison of two nested
models, rather than for a general comparison of 14 non-nested
models. For these reasons, we presented the sensitivity, specificity,
PPV and NPV at four thresholds to provide additional comparative
information about the potential clinical utility of the models.
Comparison with existing literature. Overall, the discrimination
of the best performing models is a little less good than risk models
for other cancers, such as breast (0.72–0.76) (Amir et al, 2010) and
melanoma (0.70–0.79) (Usher-Smith et al, 2014). Our AUC results
are similar to those reported in validation studies for the Driver,
Freedman, Ma, Tao and Wells models: 0.67 (95% CI: 0.66–0.69)
compared with 0.69 for the Driver model in men (Driver et al,
2007); 0.64 (95% CI: 0.61–0.66) for men and 0.59 (95% CI: 0.56–
0.61) for women compared with 0.61 (95% CI, 0.60–0.62) for men
and 0.61 (95% CI, 0.59–0.62) for women for the Freedman model
in an external population in America (Park et al, 2009); 0.69 (95%
CI: 0.68–0.71) compared with 0.64 (0.61–0.67) for the Ma model in
an external population in Japan (Ma et al, 2010); 0.69 (0.67–0.70)
compared with 0.68 (0.57–0.79) in an external population in
Germany for the Tao model (Tao et al, 2014); and 0.64 (0.62–0.66)
in women and 0.61 (0.59–0.64) in men compared with 0.68 (0.67–
0.69) in both men and women in 10-fold cross validation of the
Wells model (Wells et al, 2014). There are no published data on
performance in either development populations or validation
cohorts for the models by Guesmi et al (2010), Johnson et al (2013)
and Wei Y-S et al (2009).
Despite having the highest discrimination in this study
population, the AUC for both male and female QCancer10 models
were lower than in split-sample validation (Hippisley-Cox and
Coupland, 2015) (0.66 (0.64–0.67) and 0.70 (0.69–0.72) compared
with 0.85 (0.84–0.85) and 0.86 (0.86–0.87) for women and men,
respectively). As for all risk models, this difference may reflect a
difference in the incidence of disease or underlying distribution of
risk factors within the development and validation populations, or
a difference in the collection and/or coding of those underlying risk
factors.
For the Colditz model (Colditz et al, 2000), we were also only
able to assess the discrimination of the point score component of
the risk model as the data on population average risk of cancer and
cumulative age- and sex-specific 10-year risk incidence used to
estimate an individual-based relative risk in the model are not
published. This may explain why the discrimination in this study
(0.56 (0.54–0.58) in men and 0.50 (0.48–0.53) in women) is lower
than in a previous external validation studies (0.71 (0.68–0.74) in
men and 0.67 (0.64–0.70) in women) (Kim et al, 2004).
Table 4. Discriminatory performance measures for each of the risk models for 5 year risk of developing colorectal cancer in
women
Colditz Freedman Guesmi Johnson QCancer10 Tao Wei Y-S Wells Drivera
Ma
(simple)a
Ma (cox)a
Total n
n¼
164034
n¼
130188
n¼
202620
n¼
203390
n¼
193365
n¼
189097
n¼
194601
n¼
191475
n¼
201474
n¼
174297
n¼
174297
Incident
CRC
n ¼ 592 n ¼ 562 n ¼ 752 n ¼ 754 n ¼ 714 n ¼ 696 n ¼ 716 n ¼ 713 n ¼ 745 n ¼ 628 n ¼ 628
Top 10%
Sensitivity 12.3 16.5 11.2 19.8 19.0 18.0 11.0 18.9 17.4 19.6 19.3
Specificity 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0
LRþ 1.23 1.66 1.12 1.00 1.91 1.80 1.10 1.90 1.75 1.97 1.93
LR 0.97 0.93 0.99 0.98 0.90 0.91 0.99 0.90 0.92 0.89 0.90
PPV (%) 0.4 0.7 0.4 0.4 0.7 0.7 0.4 0.7 0.6 0.7 0.7
NPV (%) 99.6 99.6 99.6 99.6 99.7 99.7 99.6 99.7 99.7 99.7 99.7
Top 20%
Sensitivity 21.5 30.1 28.3 22.9 36.1 33.9 19.3 33.1 30.9 31.2 32.6
Specificity 80.0 80.0 80.0 80.0 80.1 80.1 80.0 80.0 80.0 80.0 80.0
LRþ 1.07 1.51 1.42 1.15 1.81 1.70 1.01 1.66 1.55 1.56 1.64
LR 0.98 0.87 0.90 0.96 0.80 0.83 0.95 0.84 0.86 0.86 0.84
PPV (%) 0.4 0.6 0.5 0.4 0.7 0.6 0.4 0.6 0.6 0.6 0.6
NPV (%) 99.6 99.6 99.7 99.6 99.7 99.7 99.6 99.7 99.7 99.7 99.7
Top 80%
Sensitivity 80.2 86.1 92.7 76.5 93.6 91.4 78.2 93.1 91.9 93.0 92.0
Specificity 20.0 20.0 20.0 20.0 20.1 20.0 20.0 20.0 20.0 20.0 20.0
LRþ 1.00 1.08 1.16 0.96 1.17 1.14 0.98 1.16 1.15 1.16 1.15
LR 0.99 0.69 0.36 1.17 0.32 0.43 1.09 0.34 0.40 0.35 0.40
PPV (%) 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
NPV (%) 99.6 99.7 99.9 99.6 99.9 99.8 99.6 99.9 99.9 99.9 99.9
Top 90%
Sensitivity 90.4 94.0 97.2 88.2 97.1 95.1 88.8 96.9 95.7 96.7 95.7
Specificity 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0
LRþ 1.00 1.04 1.08 0.98 1.08 1.06 0.99 1.08 1.06 1.07 1.06
LR 0.96 0.60 0.27 1.18 0.29 0.49 1.12 0.31 0.43 0.33 0.43
PPV (%) 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
NPV (%) 99.6 99.7 99.9 99.6 99.9 99.8 99.6 99.9 99.8 99.9 99.8
Abbreviations: LRþ ¼positive likelihood ratio; LR ¼ negative likelihood ratio; NPV¼negative predictive value; PPV¼positive predictive value.
aModels originally developed only for men.
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Implications for clinicians and policymakers. This study shows
that the performance of published risk models varies substantially
with several risk models based on easily obtainable data, such as
age, sex, BMI, smoking, alcohol consumption and physical activity,
having relatively good discrimination in a UK population. Using
the QCancer10 (Hippisley-Cox and Coupland, 2015) model, for
example, the data from this study estimates that the top 10% would
include 25% of men who later go on to develop CRC, and the top
20% would include 43%. The QCancer10 model includes variables
available within routine electronic health records and so would not
require additional data collection if access to those records could be
used to identify those eligible for screening. Excluding the term for
deprivation in the male model also made little difference to the
discrimination, so could be removed for use in countries outside
the UK. The model by Driver et al (2007) also contains variables
that would be available within routine health records or easily
obtainable (age, BMI, smoking status, alcohol consumption). The
discrimination and sensitivity are slightly lower than QCancer10,
but the advantage would be simplified data collection or extraction
and this may be preferable particularly in health systems where less
data are routinely collected.
Unanswered questions and future research. While this study can
help guide the choice of risk prediction model to identify those at
higher risk of CRC, these findings do not tell us the extent to which
using these models in place of the current age-based criteria might
improve efficiency or allow us to make recommendations about
different tests, screening intervals, preventive advice, treatment, or
age of onset of screening based on modelled risk. To answer those
questions, modelling studies are needed to explore the potential
health benefits and cost-effectiveness of different strategies. These
could be performed using microsimulation models, such as the
SimCRC (Loeve et al, 1999) or MISCAN-COLON (Loeve et al,
1999), which simulate the development of adenomas and their
3
2
5-
ye
a
r 
ris
k 
(%
)
1
0
Lowest
Deciles of risk
DriverA
B
Freedman Ma (simple)
Wells
Wells
QCancer10Ma (Cox)
Driver* Freedman Ma (simple)*
Highest
3
2
5-
ye
a
r 
ris
k 
(%
)
5-
ye
a
r 
ris
k 
(%
)
5-
ye
a
r 
ris
k 
(%
)
5-
ye
a
r 
ris
k 
(%
)
5-
ye
a
r 
ris
k 
(%
)
5-
ye
a
r 
ris
k 
(%
)
5-
ye
a
r 
ris
k 
(%
)
1
0
2.5
2
1.5
1
0.5
0
2.5
2
1.5
1
0.5
0
2.5
2
1.5
1
0.5
0
2.5
2
1.5
1
0.5
0
2.5
2
1.5
1
0.5
0
2.5
2
1.5
1
0.5
0
Lowest
Deciles of risk Highest
3
QCancer10Ma (Cox)
2
5-
ye
a
r 
ris
k 
(%
)
1
0
Lowest
Deciles of risk Highest
3 Observed
Predicted assuming a doubling of risk every 5 years
Predicted assuming constant risk over time
Observed
Predicted assuming a doubling of risk every 5 years
Predicted assuming constant risk over time
2
5-
ye
a
r 
ris
k 
(%
)
1
0
Lowest
Deciles of risk Highest
Lowest Deciles of risk Highest Lowest Deciles of risk Highest Lowest Deciles of risk Highest
Lowest Deciles of risk Highest Lowest Deciles of risk Highest Lowest Deciles of risk Highest
3
2
5-
ye
a
r 
ris
k 
(%
)
1
0
Lowest
Deciles of risk
Highest
3
2
5-
ye
a
r 
ris
k 
(%
)
1
0
Lowest
Deciles of risk
Highest
Figure 2. Model calibration. Plots of observed and predicted 5-year risk of colorectal cancer for (A) men and (B) women. *Models originally only
developed in men.
BRITISH JOURNAL OF CANCER Risk prediction models for colorectal cancer
8 www.bjcancer.com |DOI:10.1038/bjc.2017.463
progression to CRC in a large population of individuals with
distributions of risk factors reflecting those found in the general
population. By calculating baseline risks for the simulated
population using the best performing models and then modelling
age of onset of screening and choice of test using a range of
thresholds based on estimated risk, it would be possible to estimate
the expected number of CRC deaths prevented, the quality of life
years gained and the cost-effectiveness of the screening programme
compared to current practice. Implementation studies, ideally
randomised controlled trials, are then needed to assess the
feasibility of obtaining the risk factor data for each individual,
the acceptability of incorporating a stratified approach and
potential benefits and adverse consequences of incorporating such
an approach into practice. We have also only included risk models
based on phenotypic, medical history and lifestyle information in this
study as such variables are either routinely available or easily
obtainable via self-completed questionnaire. A number of risk models
incorporating both genetic and non-genetic biomarkers also exist and
may have improved discrimination and calibration. While introdu-
cing these into current practice would require fundamental changes
in infrastructure (Aronson and Rehm, 2015), progress in this area is
advancing (Hayward et al, 2017), and simple risk models, such as
those in this study, might be useful to identify those in whom
collection of additional biomarker information might be helpful.
Further research is therefore needed to assess the performance of
models incorporating these additional variables.
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